Back to top
more

Collegium Pharmaceutical, Inc. (COLL)

(Real Time Quote from BATS)

$12.09 USD

12.09
173,160

+0.20 (1.68%)

Updated Oct 17, 2019 02:57 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

A Value | A Growth | F Momentum | A VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Collegium Pharmaceutical (COLL) Q2 Earnings Surpass Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 152.63% and -1.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

COLL

Zacks Equity Research

Earnings Preview: Collegium Pharmaceutical (COLL) Q2 Earnings Expected to Decline

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

COLL

Zacks Equity Research

Collegium Pharmaceutical (COLL) Reports Q1 Loss, Tops Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 83.33% and 6.29%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

COLL

Zacks Equity Research

Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up?

During Assertio Therapeutics' (ASRT) Q1 conference call, investor focus will be on the company's progress with its neurology franchise and the NDA filing for cosyntropin.

HZNP ADRO COLL ASRT

Zacks Equity Research

Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

COLL

Zacks Equity Research

Collegium Pharmaceutical (COLL) Upgraded to Buy: What Does It Mean for the Stock?

Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

COLL

Zacks Equity Research

Collegium Pharmaceutical (COLL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

COLL

Zacks Equity Research

ASRT or COLL: Which Is the Better Value Stock Right Now?

ASRT vs. COLL: Which Stock Is the Better Value Option?

ASRT COLL

Zacks Equity Research

ASRT vs. COLL: Which Stock Should Value Investors Buy Now?

ASRT vs. COLL: Which Stock Is the Better Value Option?

ASRT COLL

Zacks Equity Research

ASRT vs. COLL: Which Stock Should Value Investors Buy Now?

ASRT vs. COLL: Which Stock Is the Better Value Option?

ASRT COLL

Zacks Equity Research

Collegium Pharmaceutical (COLL) Reports Q3 Loss, Lags Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -127.27% and -6.94%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

COLL

Zacks Equity Research

Collegium Pharmaceutical (COLL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

COLL

Zacks Equity Research

Collegium Pharmaceutical (COLL) Reports Q2 Loss, Tops Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 65.91% and 4.06%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

COLL

Zacks Equity Research

Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate

Nektar (NKTR) submits NDA to the FDA seeking approval of its analgesic opioid candidate, NKTR-181, for the treatment of chronic low back pain.

BMY NKTR COLL TEVA

Zacks Equity Research

What's in Store for Penumbra (PEN) This Earnings Season?

Penumbra (PEN) deepens its focus on driving innovation, ramping up production and expanding geographies.

PEN MGNX ARRY COLL

Zacks Equity Research

Collegium Pharmaceutical, Inc. (COLL) Sees Hammer Chart Pattern: Time to Buy?

Collegium Pharmaceutical, Inc. (COLL) Sees Hammer Chart Pattern: Time to Buy?

COLL

Zacks Equity Research

Sage Therapeutics Soars: Stock Adds 7.1% in Session

Sage Therapeutics (SAGE) was a big mover last session, as the company saw its shares rise more than 7% on the day.

SAGE COLL

Zacks Equity Research

Valeant (VRX) in Focus: Stock Moves 11.7% Higher

Valeant Pharmaceuticals International (VRX) was a big mover last session, as the company saw its shares rise nearly 12% on the day.

VRX COLL

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for November 27th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 27th:

VGR TNET CRCM COLL

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for November 22nd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 22nd:

RGA PLNT COLL CHDN

Zacks Equity Research

Collegium (COLL) in Focus: Stock Moves 6.9% Higher

Collegium Pharmaceutical (COLL) was a big mover last session, as the company saw its shares rise nearly 7% on the day amid huge volumes.

SCMP COLL

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for November 16th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 16th:

RL RGA COLL CHDN

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for November 14th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 14th:

TTWO KMT COLL ALSN

Zacks Equity Research

Collegium Pharmaceutical (COLL) Looks Good: Stock Adds 6% in Session

Collegium Pharmaceutical (COLL) shares rose 6% in the last trading session, amid huge volumes.

COLL CRBP

Zacks Equity Research

BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End

BioDelivery Sciences (BDSI) President and CEO, Mark Sirgo, is set to retire this year.

BDSI ENDP CORT COLL